Investors
Financials
Financial Calendar
January 15, 2026 – Fourth Quarter 2025 Sales
April 15, 2026 – Q1 2026 Sales
April 22, 2026 – 2025 Annual Results
June 4, 2026 – 2026 Annual General Meeting
July 21, 2026 – Q2 2026 Sales
October 8, 2026 – 2026 Half-Year Results
October 20, 2026 – Q3 2026 Sales
Financial Calendar
January 15, 2026 – Fourth Quarter 2025 Sales
April 9, 2026 – 2025 Annual Results
April 16, 2026 – Q1 2026 Sales
June 4, 2026 – 2026 Annual General Meeting
July 21, 2026 – Q2 2026 Sales
October 8, 2026 – 2026 Half-Year Results
October 20, 2026 – Q3 2026 Sales
Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update
Mauna Kea Technologies Announces its 2025 Financial Calendar
Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
Publication of the 2023 Annual Financial Report
Mauna Kea Technologies Reports Full Year 2023 Results and Q1 2024 Sales
Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank
Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate
Mauna Kea Technologies Reports Full Year 2023 Sales of €10.5m, Up +42% vs 2022
Mauna Kea Technologies Reports 74% Increase in 9-Month 2023 Sales
Mauna Kea Technologies Reports H1 2023 Financial Results
Mauna Kea Technologies Reports Second Quarter and First Half 2023 Revenue
No results found.
News
Mauna Kea Technologies Announces Major Milestone for Cellvizio® in Pancreatic Cysts with CLIMB Study Selected for ASGE Presidential Plenary Session at DDW 2026
Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom
Mauna Kea Technologies Announces CE MDR Certification For Cellvizio® and Its Associated Probes
No results found.